Barclays PLC Buys 41,424 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Barclays PLC grew its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 64.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,467 shares of the company’s stock after buying an additional 41,424 shares during the quarter. Barclays PLC owned approximately 0.21% of Spyre Therapeutics worth $3,101,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in SYRE. Amalgamated Bank purchased a new stake in Spyre Therapeutics in the 2nd quarter worth approximately $28,000. Quest Partners LLC purchased a new stake in shares of Spyre Therapeutics in the second quarter worth $36,000. SG Americas Securities LLC bought a new stake in shares of Spyre Therapeutics during the 2nd quarter valued at $130,000. Intech Investment Management LLC purchased a new position in shares of Spyre Therapeutics during the 3rd quarter valued at $246,000. Finally, Carlyle Group Inc. bought a new position in Spyre Therapeutics in the 2nd quarter worth $227,000. Institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Trading Down 1.1 %

Shares of Spyre Therapeutics stock opened at $23.59 on Tuesday. The firm has a market cap of $1.21 billion, a PE ratio of -3.16 and a beta of 2.82. The stock has a 50 day moving average of $30.11 and a 200 day moving average of $28.71. Spyre Therapeutics, Inc. has a 12 month low of $17.83 and a 12 month high of $47.97.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SYRE. Robert W. Baird raised their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Guggenheim lifted their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Finally, Wedbush restated an “outperform” rating and issued a $45.00 price target on shares of Spyre Therapeutics in a research note on Friday, November 8th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $51.50.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).